# A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes

Study · id `cardio:ct-nct04591626` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04591626](<https://clinicaltrials.gov/study/NCT04591626>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04591626

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 291 participants.

## Technical summary

Registry record NCT04591626. Randomized; double masking; primary purpose treatment. Start 2020-12-07 (actual); primary completion 2022-04-28 (actual). Results posted on 2023-05-24.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 291 participants (enrolled count; ClinicalTrials.gov record NCT04591626, source copy `cardio:ctgov-nct04591626-2023-05-24`, retrieved 2026-10-26)
- Started: 2020-12-07 (actual) (ClinicalTrials.gov record NCT04591626, source copy `cardio:ctgov-nct04591626-2023-05-24`, retrieved 2026-10-26)
- Primary completion: 2022-04-28 (actual) (ClinicalTrials.gov record NCT04591626, source copy `cardio:ctgov-nct04591626-2023-05-24`, retrieved 2026-10-26)
- Completion: 2022-04-28 (actual) (ClinicalTrials.gov record NCT04591626, source copy `cardio:ctgov-nct04591626-2023-05-24`, retrieved 2026-10-26)
- Results first posted: 2023-05-24 (ClinicalTrials.gov record NCT04591626, source copy `cardio:ctgov-nct04591626-2023-05-24`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04591626, source copy `cardio:ctgov-nct04591626-2023-05-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04591626-2023-05-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes
- Acronym: AWARD-CHN3
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Dulaglutide
- Intervention (Drug): Placebo
- Intervention (Drug): Insulin Glargine
- Lead sponsor: Eli Lilly and Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 95423a741bedd86af0dae43f25482597832705eb033357cfe0765eef9303cde6
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
